STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more

The FDA is reviewing a drug approval program initiated by former commissioner Marty Makary after receiving mixed feedback, and has launched a safety study of the mifepristone abortion pill, potentially leading to distribution restrictions under the Trump administration. Antiabortion groups and Republican lawmakers supported the study, which is expected to take six months.